Search
Industry News丨Accro Bioscience Announces Completion of $50 Million Series C Financing to Accelerate Pipeline for Inflammatory and Immune Diseases
6 day ago /
Read about 0 minute
Author：小编
On May 18, 2026, Accro Bioscience, a clinical-stage biotechnology company focused on 'regulated cell death,' announced the completion of a $50 million Series C financing. This round of financing was led by OrbiMed, with participation from TCG Crossover, Lilly Asia Ventures, Cenova Ventures, and existing shareholders Shenzhen Capital Group and Yuan grain Holdings. The proceeds will be used to advance the Phase IIb clinical trial of the RIPK2 inhibitor AC-101 for the treatment of ulcerative colitis (UC) and to accelerate the development of multiple other pipelines for inflammatory and immune diseases.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
